Waratah Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-14,237
Closed -$772K – 126
2024
Q1
$772K Buy
+14,237
New +$725K 0.02% 120

Other funds holding BMY

Waratah Capital Advisors's BMY Position: Q2 2024 in Review

Waratah Capital Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 14,237 shares — an estimated $772K sold.

Waratah Capital Advisors first reported a position in BMY in Q1 2024 and held it in 1 quarter. The position peaked at $772K in Q1 2024. 2,154 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

  • Waratah Capital Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
  • Waratah Capital Advisors sold 14,237 Bristol-Myers Squibb shares in Q2 2024, an estimated $772K.
  • Waratah Capital Advisors first reported a position in Bristol-Myers Squibb in Q1 2024 and held it in 1 quarter.
  • Waratah Capital Advisors's Bristol-Myers Squibb position peaked at $772K in Q1 2024.
  • 2,154 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Waratah Capital Advisors's 13F filing for Q2 2024, filed 12 Aug 2024.